Precigen, Inc. (PGEN) AI Stock Analysis

Precigen, Inc., based in Germantown, Maryland, is a biotechnology company advancing gene and cellular therapies. Founded in 1998 and previously known as Intrexon Corporation until January 2020, the company develops disease-modifying therapeutics and specialized biological tools. Its portfolio includes genetically engineered swine for regenerative medicine, reproductive technologies, and the UltraVector platform for genetic assembly. Precigen has also developed mbIL15 for immune cell enhancement, the Sleeping Beauty non-viral transposon/transposase system, AdenoVerse engineered adenovector libraries, and L. lactis bacteria. In addition, its technology suite features the RheoSwitch inducible gene switch, UltraCAR-T for cancer therapies, and AdenoVerse Immunotherapy platforms.

Precigen reported FY2025 revenue of $9.7M, an increase of 146.7% from $3.9M in FY2024, following a 5-year revenue CAGR of -21.3% from FY2020 to FY2025. Gross margin was 37.1% in FY2025, recovering from -8.7% in FY2024. However, operating margin stood at -1100.8% and net loss expanded to -$250.6M, resulting in an EPS of -$1.39. In the trailing twelve months ended June 30, 2026, revenue totaled $85.7M, supported by quarterly revenue growth of 6322.7% year-over-year. TTM operating margin improved to 41.2%, though profit margin remained negative at -184.0% with an EPS of -$1.04.

As of June 30, 2026, Precigen held $38.2M in cash and short-term investments against total debt of $98.3M, resulting in net debt of $60.1M. Shareholders' equity was $43.6M, yielding a debt-to-equity ratio of 2.26, while the current ratio stood at 4.58. Operating cash flow was -$87.8M in FY2025, and free cash flow was -$89.8M. Cash usage in FY2025 included $2.0M in capital expenditures and $2.2M in share buybacks, while the share count increased 107.6% over the past 5 years.

Precigen carries a market capitalization of $2.28B and an enterprise value of $2.72B. The stock trades at a forward P/E of 16.9x, slightly below the 17.3x median of its US-listed Healthcare peers. Its price-to-sales multiple is 26.7x and EV-to-revenue is 31.7x, compared to the peer median price-to-sales of 4.1x. Over the past year, Precigen achieved a return of 83.1%, outperforming the S&P 500 (SPY) return of 16.8%, while its 5-year return of 37.4% trailed the S&P 500 return of 83.0%.

Wall Street coverage includes 2 Strong Buy, 1 Buy, and 1 Hold ratings, with zero Sell or Strong Sell recommendations. The mean price target of $13.65 indicates an upside of 113.6% over the last close of $6.39. For the fiscal year ending December 31, 2026, consensus estimates project revenue of $238.8M and an EPS of $0.22. Precigen has beaten EPS estimates in 3 of the last 4 quarters, and its next earnings date is scheduled for November 12, 2026.

This page is an AI-written research summary of Precigen, Inc. (PGEN). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: PGEN income statement, PGEN balance sheet, PGEN key metrics, PGEN analyst forecast, PGEN chart. See the PGEN stock overview for the latest quote and news.